Shares of Illumina were lower Tuesday after the biotech firm cut its third-quarter sales expectations to $607 million, that’s down more than 3% from the midpoint of its prior guidance.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
